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Reduction of defibrillation threshold 
and safety of usage of a new model of 
subcutaneous defibrillation lead
ABSTRACT
This study was designed to evaluate the performance of a new single coil model of a subcutaneous 
defibrillation lead (Medtronic, 6996S) by assessing its capability to lower the defibrillation threshold. The 
6996S lead is a permanent unipolar subcutaneous lead with a short (15 cm) defibrillation coil. Additionally, 
the safety of the lead and its chronic stability were evaluated. 
The investigation was performed in patients who underwent implantation of an ICD system consisting of 
a single coil RV lead with a left sub-clavicular Active Can ICD. In these patients, the DFT was determined 
twice during the implantation procedure with a binary search protocol, once with an ICD system which 
included the 6996S lead (RV → Can + SQ), and once without the 6996S lead (RV → Can). The order in 
which the implanted system configurations were tested was randomised.
Between June 2004 and February 2006, 32 patients were enrolled into the study. Post-implantation follow-up 
was of at least three-month duration. The DFT test results of 31 patients have been analysed. The average 
DFT of (Can → RV) and (Can + 6996S → RV) were respectively 14.3 ± 9.9 J and 10.5 ± 6.2 J (p = 0.007). 
The addition of the 6996S lead with 15 cm coil reduced the average DFT by 27%, which is about 80% of 
the DFT reduction obtained with the 6996 lead with 25 cm coil. Adverse events, predominantly related 
to progression of heart failure, were observed in eight (26%) patients during the study and were related 
neither to the particular 6996S lead model, nor to the implant procedure.
The short-coil (6996S) SQ lead significantly reduced mean DFT. The implant procedure is safe, but the 
6996S lead requires / warrants long-term surveillance / observation due to retraction of the tip of the lead, 
ranging from 1 to 4 cm, found in eight of 14 patients (57%) implanted with this lead model.
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Introduction
Patients at risk of sudden cardiac arrest should be se-
cured with an implantable cardioverter-defibrillator (ICD) 
system. High voltage circuit of the ICD is the part of 
the device that is crucial in terms of saving life. Now-
adays, ICD systems consist of two parts through which 
high energy is delivered to the heart: one of which is 
intracardiac — defibrillation-coil right ventricular lead, 
and the other one extracardiac — the active can of 
the device. The implantation procedure comprises an 
assessment of appropriate tachyarrhythmia detection 
capability of the system as well as the ability of the sys-
tem to provide adequate defibrillation therapy — defibril-
lation threshold testing (DFT). The technical evolution 
of the ICD systems (e.g. 40 J devices) decreases the 
incidence of high DFT. Though, if present, resolving 
high-DFT issues can represent a very challenging task 
for implanting physicians. One of the most efficient ways 
in that situation is the implantation of an additional, 
subcutaneous lead, which decreases the assessed 
high defibrillation threshold. Subcutaneous patches 
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have been shown to be less effective and cause more 
complications than array or single coil electrodes [1–3].
Purpose of the study 
This study was designed to evaluate the perfor-
mance of a new model single coil subcutaneous 
defibrillation lead (Medtronic 6996S) by assessing its 
capability to lower the defibrillation threshold demon-
strating a significant reduction of the mean DFT with 
the Can + 6996S → RV configuration compared to the 
mean DFT for the Can → RV standard configuration at 
implant. Additionally, the safety of lead implantation and 
chronic stability were evaluated.
Methods
The clinical investigation of the 6996S lead was 
a multi-centre, randomised, prospective, clinical re-
search study. Between June 2004 and February 2006, 
five centres (one in Germany, four in Poland) enrolled 
32 patients in the study. The 6996S lead is a permanent 
unipolar subcutaneous lead with a single defibrillation 
coil. It was designed to provide improved ease of use com-
pared to the market-released model 6996 (Medtronic), 
while maintaining improved defibrillation characteris-
tics. The lead comprises a DF-1 connector, a silicone 
lead body, a platinum-iridium coil electrode and a distal 
silicone tip. Its design is similar to the design of the 
6996 lead model, with the main difference being the 
reduction in coil length from 25 cm to 15 cm. 
Figure 1. Binary search protocol
The investigation was conducted in compliance 
with the study protocol, EN 540, the Declaration of 
Helsinki, and in accordance with institutional ethic 
board guidelines. An enrollment rate of approximately 
60 patients was anticipated in order to provide at least 
50 patients for complete analysis of the DFT data and 
25 patients chronically implanted with the 6996S lead 
for a three month follow up. Patient enrollment was 
consecutive. An interim analysis was planned after 
36 patients.
All patients were implanted with single RV-coil de-
fibrillation leads (Medtronic Sprint 6943 or Sprint 6932). 
The ICD devices were Medtronic GEM III VR/DR or 
Medtronic Marquis VR / DR. DFT was determined twice at 
implant, according to the binary search protocol (Fig. 1). 
Two configurations labelled (A) and (B), respectively 
with (Can + 6996S → RV) and without (Can → RV) 
the 6996S lead, as an active part of the defibrillation 
system, were tested. The order of implantations of par-
ticular types of systems, as well as the DFT assessment 
sequence (A → B or B → A), were set in a randomised 
manner. With configuration A tested first, the 6996S lead 
was explanted after the DFT test to avoid its potential 
influence on the test with the B configuration. Hence, 
these patients did not have the 6996S lead chronically 
implanted and did not require post-implant follow-up, 
except for adverse events related to the insertion of 
the subcutaneous lead that occur due to the implant 
protocol. Patients in whom configuration A was tested 
secondly had the 6996S lead chronically implanted 
and had to be followed after one, three and six months 
thereafter, until the last patient in the study had com-
pleted the three-month follow-up. For the purpose of 
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the study, data collection was required only until the 
three-month follow-up visit to meet the study objec-
tives. Any occurring adverse events and unscheduled 
follow-up visits mandating device interrogation, repro-
gramming or patient discontinuations in the study were 
documented as well (Fig. 2). In a patient who had been 
randomised to an arm of the study and not to receive 
the 6996S lead chronically but had a high DFT threshold 
or did not meet the implant criteria with the Can → RV 
lead configuration, the physician might have decided 
to reimplant the 6996S lead after the Can → RV lead 
system was tested. Once this was done, the patients 
had to be followed according to the protocol for at least 
three months. All adverse events were reported to the 
study sponsor (Medtronic Bakken Research Centre). 
The list of anticipated adverse events was divided into 
two categories: ICD implant-related, and subcutaneous 
lead-related.
Statistical analysis
Statistics for the categorical variables are reported 
as counts and percentages, and as mean values and 
standard deviation for continuous variables. To test 
for difference in distributions, we used the two-sided 
Fisher test for proportions (a = 0.05). For paired 
continuous data, we applied one-sided paired t-test 
(a = 0.025) after checking that relevant assumptions 
were met. For testing whether using amiodarone 
leads to a higher DFT, the non-parametric Wilcoxon 
two sample test (a = 0.05) was used, as the normality 
assumption for t-test was not met. The analysis was 
performed using Excel 7, with the exception of the 
statistical tests which were performed using the SAS 
9.2 software.
Figure 2. Model 6996S study design
Results
An interim analysis was planned after 36 patients 
had been enrolled in the study. However, due to an 
unexpectedly low enrollment rate, the interim analysis 
was performed prematurely after the inclusion of 32 pa-
tients. Having met the primary endpoint of the study, 
further enrollment was discontinued. 
Patient demographics, indication for ICD implanta-
tion and cardiovascular history are shown in Table 1. 
Almost all patients in the study were male (31 male). 
In 69% of the cases, the aetiology of heart failure was 
ischaemic, with a mean left ventricular ejection fraction 
of 31.5 ± 10.6%. The patients’ functional status as 
assessed according to NYHA classification was class 
I in 13% of cases, class II — 53%, class III — 31%, and 
class IV — 0%. Half of the examined patients were 
treated with amiodarone.
There was one case of failure of ventricular fibrillation 
induction, so the final analysis included only 31 patients. 
Figure 3 shows anterior-posterior and lateral X-ray 
images of the intended lead positions in a patient from 
the 6996S study compared to parallel images from 
a 6996 study patient as a reference. 
16 patients were randomised to have the 6996S 
lead-based configuration tested first, while in the re-
maining 15 participants it was tested second. In two 
patients without the 6996S lead, the necessary backup 
shocks required using 34 J and 35 J devices, while the 
other backup shocks were obtained at 30 J.
Five patients required deviations from the Binary 
Search Protocol, mainly due to the failure to defibrillate 
at high energy with the non-6996S lead configuration, 
making the execution of the protocol incomplete. In 
these cases, the lowest successful defibrillation energy 
of a test shock or backup shock was recorded as the DFT. 
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Table 1. Patient demographics, indication for ICD implantation, cardiovascular history of examined group of patients
Patient demographics (mean ± SD) Number
Patient gender: male 31/32 (97%)
Patient height 172.6 ± 7.5 32
Patient weight 76.2 ± 11.6 32
Patient age 59.5 ± 11.0 31
Indication for ICD implant Number
Cardiac arrest 15/32 (47%)
LVEF < 30 at least 1 month prior MI 6/32 (19%)
Spontaneous recurrent, poorly tolerated, sustained VT 22/32 (69%)
Non sustained ventricular tachycardia 5/32 (16%)
Previous RV lead with a RV coil only and true bipolar sensing 4/32 (13%)
Cardiovascular history (mean ± SD) Number
Coronary artery disease 22/32 (69%)
Congestive heart failure 2/32 (6%)
Hypertension 9/32 (28%)
NYHA Functional Classification 
class I 
class II 
class III 
class IV
 
5/32 (16%) 
17/32 (53%) 
10/32 (31%) 
0/32 (0%)
Ischaemic aetiology 22/32 (69%)
LVEF (%) with echo 31.5 ± 10.6 31/32 (97%)
Syncope/presyncope 5/32 (16%)
Acute myocardial infarction 7/32 (22%)
Chronic myocardial infarction 17/32 (53%)
ICD — implantable cardioverter-defibrillator; SD — standard deviation; LVEF — left ventricular efection fraction; NYHA — New York Heart  
Association
In order to take into account the above-mentioned 
exceptions, a separate analysis of conservative DFTs 
was performed. A conservative DFT was defined as: 
 — 30 J for the two DFTs with the non-6996S lead 
configuration where the necessary backup shocks 
were obtained with 34 and 35 J; 
 — the lowest possible DFT in the four non-6996S 
configurations that deviated from the Binary Search 
Protocol; 
 — raw DFT in all other cases. 
Note that this definition of conservative DFT as-
sumes that all shocks at non-tested energy levels were 
successful in the non-SQ lead configurations, and un-
successful in the configurations with SQ lead. 
To evaluate the difference between DFT with and 
without SQ leads, a single-sided paired t-test was per-
formed. The assumptions of the t-test were met, as the 
sample size was large enough (n = 31) and the differ-
ences were statistically significant. The DFT Can → RV and 
DFT Can + 6996S → RV were 14.3 ± 9.9 J and 10.5 ± 6.2 J 
respectively (p = 0.007, a = 0.025) (Fig. 4). 
The results were similar with conservative DFT values: 
DFT Can → RV and DFT Can + 6996S → RV were 13.1 ± 8.3 J 
and 10.5 ± 6.2 J respectively (p = 0.01, a = 0.025). 
The correlation coefficient between the initial and 
second DFT values in the same patient was assumed 
to be equal to 0.53 using the protocol for equal config-
urations — a value derived from the evaluation studies 
of the 6996 lead (ACAT II study). Figure 5 presents 
the DFT results for each patient, obtained for the two 
configurations with alternative testing patterns. The 
actual coefficient of correlation between both DFT 
values was 0.57. 
Figure 6 shows the cumulative DFT distributions 
of Can → RV and Can + 6996S → RV configurations, 
that indicate the fraction meeting the implant criterion of 
18 J ICD as defined in the clinical protocol of 74.2% and 
93.5% respectively. A Fisher test for proportions resulted 
in a two-sided p-value of 0.08 for the raw DFTs, and in 
a two-sided p-value of 0.15 for the conservative DFTs.
With the normality assumption for t-test not met, for test-
ing whether using amiodarone leads to a higher DFT (Tab. 2), 
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Figure 3. Typical examples of anterior-posterior and lateral X-ray images of the intended 6996S and 6996 implant positions 
taken from one of the patients in the 6996S study and from a 6996 patient as a reference
6996, AP view 6996, lateral view
6996S, AP view 6996S, lateral view
Figure 4. DFT obtained from raw DFT data of ICD configurations without and with one lead model 6996S (n = 31)
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the non-parametric Wilcoxon two sample test was 
used. The DFT values obtained without SQ were not 
significantly different in patients with versus without 
amiodarone (p = 0.45), also for the conservative DFT 
values (p = 0.33). Also, no significant differences in 
DFT with SQ were seen in patients with versus without 
amiodarone (p = 0.08), even though the p value ap-
proximated to the level of significance. The conservative 
DFTs with SQ were equal to the raw DFT values. 
During the study, adverse events were observed in 
eight (26%) patients. All adverse events and their out-
comes are summarised in Table 3. The most frequent 
complication during the entire follow-up period was 
progression of heart failure, but only in one case did it 
occur on the day of ICD implantation, and this was not 
related to the procedure. None of the adverse events 
were related to the implant procedure or the chronic 
performance of the investigated lead model.
Mean DFT impedance at DFT shock energy for the 
Active Can → RV test configuration (n = 30) was sig-
nificantly higher than for the Active Can + 6996S → RV 
test configuration (n = 30) — respectively 63.4 ± 8.9 Ω 
and 50.3 ± 7.4 Ω (p < 0.0001). 
Similarly, a significantly higher value of mean DFT 
impedance at 30J shock energy was observed for the 
Active Can → RV test configuration (n = 26) compared 
to the Active Can + 6996S → RV test configuration 
(n = 30) — respectively 65.0 ± 8.4 Ω and 50.0 ± 6.3 Ω 
(p < 0.0001).
X-ray images of patients with chronically implanted 
6996S leads were visually examined. Coil retraction 
was estimated according to lateral and A-P views at 
the beginning and at the end of the follow-up period. 
Radiological reference points were vertebrae, tissue 
structures, metal sutures, and eventually the elec-
trodes of other leads. Given small angular inter-patient 
differences in X-ray images, resulting from the small 
alterations in the position and orientation of the X-ray 
source relative to the patient’s thorax, the accuracy of 
coil retraction estimation is limited to approximately 
1–2 cm. X-rays from at least two follow-up episodes 
were available from 14 patients who received a chronic 
6996S implant. The episodes and retraction results are 
shown in Table 4. The estimated tip retraction was zero 
(n = 6), 1 cm (n = 2), 3 cm (n = 1) and 4 cm (n = 1), 
with a mean value of 1.2 ± 1.3 cm. Two patients had 
both one- and three-month follow-ups, showing no 
additional displacement. 
Discussion
Implantation of ICD is nowadays the main therapeu-
tic approach in patients with life-threatening arrhythmias 
as well as in those with no arrhythmic events but with 
markedly impaired left ventricular function [4–9]. Effi-
cient and safe treatment of patients with ICD depends 
on proper settings of the device, including a sufficient 
safety margin of energy delivered during defibrillation. 
Therefore defibrillation threshold testing is a pivotal 
element of the implantation procedure in many clinical 
centres. There are various possible approaches to 
defibrillation threshold testing, primarily regarding its 
specific dimensions such as timing and method [10]. 
Moreover, taking into account the presumed perils 
of cardiac arrest, many centres do not include this 
Figure 5. DFT for configuration with 6996S plotted against 
DFT for configuration without 6996S
Figure 6. Cumulative DFT distribution of Can → RV and 
Can + 6996S → RV configurations
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Table 4. 6996S tip displacement
Patient Initial X-ray Second X-ray Estimated tip retraction [cm]
6996002 PHD 3 M 2
6996003 PHD 3 M 2
6996005 PHD 1 M 3
6996013 PHD 1 M 1
6996014 PHD 1 M 2
6996015 PHD 1 M 0
6996018 1 M 3 M 0
6996020 PHD 1 M 0
6996021 PHD 1 M 1
6996023 PHD 1 M 2
6996026 PHD 1 M 0
6996029 PHD 1 M 4
6996031 PHD 1 M 0
6996032 PHD 1 M 0
PHD — follow up at hospital discharge; 1M — one month follow-up; 3M — three month follow-up
Table 2. DFT distributions categorised for 6996S — no 6996S, and amiodarone — no amiodarone
DFT All Amiodarone No amiodarone
All 14.1 ± 8.8 J (n = 15) 10.7 ± 7.9 J (n = 16)
6996S 10.5 ± 6.2 J (n = 31) 12.2 ±6.2 J (n = 15) 8.8 ± 5.9 J (n = 16)
No 6996S 14.3 ± 9.9 J (n = 31) 16.1 ± 10.7 J (n = 15) 12.7 ± 9.2 J (n = 16)
Table 3. Summary of all observed adverse events
Patient Description Nr days 
post- 
implant
System 
related
6996S 
related
Procedure 
related
Action Adverse 
event 
resolved
001 Patient died due to heart 
failure
49 No No No   –
003 Colitis induced by 
antibiotics
–7 No No No Cefnoxin therapy Yes
004 Significant increase in 
IEGM
1 Yes No   Reposition RV lead; 15 J 
test shock successful
Yes
005 Shocks in sinus 
tachycardia
67 No No No Modify therapy and 
reprogramme ICD
Yes
011 Ischaemic stroke 88 No No No   Yes
013 Ventricular tachycardia 
and ICD therapies
41 No No No Increase dose of beta- 
-blocker; reprogramme ICD
Yes
015 Pulmonary oedema 90 No No No Diuretic pharmacotherapy Yes
024 Progression of heart 
failure symptoms
0 No No No   Yes
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procedure at all in their standard approach [11]. The 
complication rate of routine DFT testing however is very 
low (less than 0.2%) [12]. One of the important advan-
tages of DFT testing is the assessment of successful 
conversion of ventricular fibrillation to sinus rhythm 
with a safety margin of maximal output of the ICD 
(usually ≥ 10 J). In the literature there is plentiful data 
regarding this problem and showing a large dispersion 
of incidence of high DFT among ICD patients, ranging 
from 3 to 12% [13–16].
The presence of a high defibrillation threshold and 
its probabilistic character warrant taking adequate 
action in order to lower the threshold. In modern de-
vices there are some software-based solutions to this 
problem. The most important one is the possibility 
of changing shock polarity or defibrillation impulse 
waveform [17]. Another way to resolve the problem 
of a high defibrillation threshold is the implantation of 
a subcutaneous array or patch. 
Subcutaneous leads were introduced into the 
trouble-shooting armentarium for high defibrillation 
threshold in ICD devices in the 1990s. Due to the tech-
nical development, it was possible to replace patches 
with arrays, with the latter ones initially constructed 
as three-finger designs, subsequently evolving into 
single-body subcutaneous leads [18]. 
There are convincing published findings confirming 
that the application of SQ leads is a very effective way 
of reducing the defibrillation threshold both in short 
and long-term observations [19–22]. However, as with 
every invasive procedure, implantation of SQ lead may 
lead to difficulties or complications. Periprocedural 
complications are very rare (e.g. pneumothorax) but 
long-term lead-related complications occur in 7–9% 
of cases (infections, dislocations) [18]. They are inde-
pendent of the type of SQ lead and are discovered by 
detailed follow-up consisting of serial chest radiographs 
and repeated DFT testing. Some authors claim the 
single-element leads to be superior due to their higher 
feasibility of implantation [18, 20].
In the present study, we investigated a new model 
of single-element subcutaneous defibrillation leads. The 
lead was designed to improve the ease of use compared 
to a previously market-released model 6996. The main 
difference between these two types is the coil length 
(25 cm vs 15 cm). The length of the coil in the 6996S 
lead was chosen based on computer modelling show-
ing that a SQ lead with 12 cm coil length was able to 
further reduce DFT by roughly 70% of the reduction 
calculated for the 25 cm coil model 6996 [23]. The 
tip of the 6996 lead is placed on a patient’s back, and 
is wrapped around the lateral wall of the thorax. The 
shorter 6996S lead ends at the lateral wall of the thorax 
in the medial axillary line. 
The main finding of our study is a significant reduc-
tion of defibrillation threshold achieved by adding the 
studied lead to a conservative ICD system configura-
tion, although problems with enrollment of a sufficient 
number of patients existed. 
The binary search protocol was deviated from for the 
CAN → RV configurations in five patients because of un-
successful defibrillation attempts at lower test energies 
and the necessity of using back-up ICD shocks. In these 
patients, successful defibrillation energy of a test shock 
or backup shock were considered the DFT values. The 
data from these patients was not excluded from the 
study. The lowest successful back-up shock energy was 
regarded as the DFT. Such an approach concerning 
the back-up shocks as surrogates for DFT was used 
only in patients without the 6996S lead. Thus, these 
higher DFTs (resulting from deviations of the binary 
search protocol) increased the DFT difference between 
the group without and the group with the 6996S lead, 
and reduced the p-value in the statistical comparison. 
In order to ensure that the statistical significance of the 
DFT difference was not due to the inclusion of these 
DFTs, a conservative DFT was defined as one energy 
level above the highest failed test energy level, which 
in turn is the lowest possible DFT that could have been 
obtained, with a compliant protocol execution. This 
definition of a conservative DFT assumes that all test 
shocks missing in the protocol would have been suc-
cessful. According to the above-mentioned problems, 
we also searched for statistical significance of the 
conservative DFT reduction. Both types of data used 
revealed a significant reduction in DFT with the addition 
of the 6996S lead. 
To the best of our knowledge, in unselected pop-
ulations of patients from different centres, the mean 
DFT is approximately ≤ 10 J [24, 25]. According to the 
results of our study, we stated that the mean defibrilla-
tion threshold was higher than expected, based on the 
above-mentioned literature data. The higher DFT values 
seen in our study made it possible to demonstrate the 
ability of the 6996S lead to significantly reduce DFT in 
high-DFT patients, normally only sparsely represented 
in other study populations.
One of the strongest predictors of a higher defibrillation 
threshold is chronic administration of amiodarone [17] 
but data regarding this problem is conflicting [26]. In 
our study, we did not observe differences in values of 
DFT according to the chronic treatment of amiodarone.
An important finding of our study is the demonstra-
tion of significant defibrillation impedance reduction 
with the 15 cm coil lead. This observation is of practical 
relevance since the application of single coil leads and 
active can systems produces higher defibrillation imped-
ance compared to dual coil leads (RV + SVC system), 
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while decreasing DFT by subcutaneous leads is asso-
ciated with the reduction of DF impedance.
Model 6996S was relatively stable, although in 
a considerable minority withdrawal of the coil was ob-
served up to 4 cm, potentially resulting in a DFT increase 
higher than the 1.2 J (based on the regression analysis). 
This increase, although acceptable in the study, may be 
unacceptable in future clinical practice when the 6996S 
lead is implanted in high DFT patients. 
Therefore, provisions in the lead design that would 
enhance lead stability, such as distal and proximal 
fixation, are expected to improve the stability of DFT 
and lead position.
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